title: Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl.
abstract: In order to develop a preferable once-a-day oral tablet formulation, various formulations of three-layered tablets containing tamsulosin HCl as a hydrophilic model drug were evaluated and compared with a commercial reference, tamsulosin OCAS®. When the test tablet was exposed to a release medium, the medium quickly permeated to the mid-layer and the two barrier layers swelled surrounding the mid-layer rapidly. Volume expansion showed faster and enough swelling of the three-layered tablet up to 2 h. Larger amount of barrier layers caused reduced release kinetics and a high molecular weight polymer showed more resistance against agitation force. A formulation with water-soluble mid-layer showed fast erosion decreasing its volume significantly. On the pharmacokinetic study, the mean ratio of area under the curve (AUC) and C(max) for the test formulation to the reference was 0.69 and 0.84, respectively, showing that the absorption of the drug was less complete than the reference. Plasma concentration at 24 h of the test formulation was higher than the reference. The Wagner-Nelson method showed that decreased initial dissolution rate might be the cause of the less complete absorption. On considering in vitro-in vivo correlation (IVIVC), level A, the reference (R²=0.981) showed more linear relationship than the test (R²=0.918) due to the decreased dissolution and absorption rate of the formulation. This result suggests that the in vitro dissolution profiles and release kinetics might be useful in correlating absorption kinetics as well as overall plasma drug concentration-time profiles for formulation studies.
authors.affiliation: GL PharmTech Corp, Seongnam, Gyeonggi 462–807, South Korea.
authors.forename: Jun Sang
authors.initials: JS
authors.lastname: Park
authors.forename: Ji Yeon
authors.initials: JY
authors.lastname: Shim
authors.forename: Jung Soo
authors.initials: JS
authors.lastname: Park
authors.forename: Myung Jae
authors.initials: MJ
authors.lastname: Lee
authors.forename: Jong Min
authors.initials: JM
authors.lastname: Kang
authors.forename: Sung Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Min Chang
authors.initials: MC
authors.lastname: Kwon
authors.forename: Young Wook
authors.initials: YW
authors.lastname: Choi
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Jeong
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations; D004285:Dogs; D004334:Drug Administration Schedule; D008970:Molecular Weight; D012995:Solubility; D013449:Sulfonamides / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D013607:Tablets / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D000077409:Tamsulosin; D013997:Time Factors
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D003692:Delayed-Action Preparations; D013449:Sulfonamides; D013607:Tablets; D000077409:Tamsulosin